Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting - Sorbonne Université
Journal Articles European Radiology Year : 2021

Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting

Abstract

This review explains in simple terms, accessible to the non-statistician, general principles regarding the correct research methods to develop and then evaluate imaging biomarkers in a clinical setting, including radiomic biomarkers. The distinction between diagnostic and prognostic biomarkers is made and emphasis placed on the need to assess clinical utility within the context of a multivariable model. Such models should not be restricted to imaging biomarkers and must include relevant disease and patient characteristics likely to be clinically useful. Biomarker utility is based on whether its addition to the basic clinical model improves diagnosis or prediction. Approaches to both model development and evaluation are explained and the need for adequate amounts of representative data stressed so as to avoid underpowering and overfitting. Advice is provided regarding how to report the research correctly.

Domains

Imaging
Fichier principal
Vignette du fichier
Halligan2021_Article_WhyDidEuropeanRadiologyRejectM.pdf (267.59 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03230630 , version 1 (20-05-2021)

Identifiers

Cite

Steve Halligan, Yves Menu, Sue Mallett. Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting. European Radiology, In press, ⟨10.1007/s00330-021-07971-1⟩. ⟨hal-03230630⟩
17 View
22 Download

Altmetric

Share

More